Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analysis of the Influence of Sex in 507 Patients With Moderate-to-Severe Atopic Dermatitis: Spanish Atopic Dermatitis Registry (BIOBADATOP).

Actas dermo-sifiliograficas·2026

Same author

Generalized Pustular Psoriasis: Review and Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

Actas dermo-sifiliograficas·2025

Same author

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Same author

[Translated article] Expert Recommendations on Topical Therapy for Psoriasis from the Spanish Psoriasis Working Group (GPS).

Actas dermo-sifiliograficas·2025

Same author

[Translated article] Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis.

Actas dermo-sifiliograficas·2025

Same author

Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis.

Actas dermo-sifiliograficas·2025

Search research articles

Related Experiment Video

Updated: May 11, 2026

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

Immunogenicity in biologic therapy: implications for dermatology.

J M Carrascosa¹

¹Servei de Dermatologia, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. jmcarrascosac@hotmail.com

Actas Dermo-Sifiliograficas

|April 30, 2013

Summary

All biologic drugs are immunogenic, potentially affecting treatment efficacy and safety. Understanding and managing immunogenicity is crucial for optimizing biologic therapy in psoriasis.

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

Related Experiment Videos

Last Updated: May 11, 2026

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

Area of Science:

Immunology
Pharmacology
Dermatology

Background:

Biologic drugs, including fully human ones, are inherently immunogenic.
This immunogenicity can trigger an immune response, leading to antidrug antibodies.
Antidrug antibodies may impact drug levels, efficacy, and safety profiles.

Purpose of the Study:

To highlight the significance of immunogenicity in biologic therapy for psoriasis.
To emphasize the dynamic nature of immunogenicity in long-term treatment.
To underscore the importance of managing immunogenicity for treatment optimization.

Main Methods:

Review of existing knowledge on biologic drug immunogenicity.
Analysis of the impact of antidrug antibodies on drug efficacy and safety.
Discussion of immunogenicity management strategies in psoriasis treatment.

Main Results:

Biologic drugs consistently elicit immune responses, forming antidrug antibodies.
These antibodies can neutralize biologic drugs or accelerate their clearance.
Immunogenicity is a key factor in secondary loss of response to biologic therapies.

Conclusions:

Managing immunogenicity is essential for effective and safe long-term biologic therapy in psoriasis.
Understanding immunogenicity aids in optimizing treatment strategies and predicting patient response.
Tailoring therapy based on immunogenicity can improve patient outcomes.